← 返回前沿论文

肿瘤内 CD39(+) T 细胞亚群的位置预测非小细胞肺癌的不同结局

英文原题:Location of CD39(+) T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer.

PubMed 2023/08/01(内容时间) J Immunother Cancer Q1 · IF 11.7(JCR 2025)

研究概要

了解CD39+ T细胞群体在NSCLC中的分布模式和位置对于理解其预后影响是必要的。本研究提供了对CD39+ T细胞的空间和功能特征及其对患者预后意义的更深入理解。

研究思路结论见上方概要

对非小细胞肺癌(NSCLC)中免疫抑制通路的机制性理解有所提升,对于开发新的诊断和治疗方法至关重要。在此,我们研究了外核苷酸酶CD39和CD73在NSCLC中的预后意义。

CD39、CD73和CD103的表达及定位在162例早期初治NSCLC患者队列中通过多重免疫荧光进行数字化定量,并与患者预后相关联。通过流式细胞术评估了不同细胞群体中的表达。对消化后的NSCLC肿瘤组织中的CD4+和CD8+T细胞进行了靶向RNA-Seq,并分析单细胞RNA-Seq数据以探究CD39+T细胞群体的功能意义。

我们证明,对早期未经治疗的NSCLC患者进行流式细胞术检测显示,肿瘤组织中自然杀伤(NK)细胞、成纤维细胞和T细胞中CD39表达上调。CD73表达主要见于肿瘤组织中的成纤维细胞和Epcam+细胞。在一个包含162例早期未经治疗的NSCLC患者队列中,多重免疫荧光显示,CD39表达主要定位于肿瘤间质,而CD73表达在肿瘤巢和间质之间分布相当,并且肿瘤间质中CD39和CD73高表达与5年时较差的无复发生存期(RFS)相关。此外,我们发现位于肿瘤巢中的CD8+T细胞表达CD103,并且肿瘤巢中CD39+CD103+CD8+ T细胞的密度预测5年时RFS改善。靶向RNA-Seq显示,NSCLC的肿瘤微环境上调CD4 + T细胞中的调控通路以及CD8 + T细胞中的耗竭,并且对单细胞RNA测序数据集的分析显示,CD39 + CD4 + 细胞富集于Treg特征基因集,而CD39 + CD103 + 细胞毒性T淋巴细胞显示提示耗竭性细胞毒性表型的基因特征,并伴有CXCL13表达上调。

展开英文摘要原文

PURPOSE: An improved mechanistic understanding of immunosuppressive pathways in non-small cell lung cancer (NSCLC) is important to develop novel diagnostic and therapeutic approaches. Here, we investigate the prognostic significance of the ectonucleotidases CD39 and CD73 in NSCLC. EXPERIMENTAL DESIGN: The expression and localization of CD39, CD73 and CD103 was digitally quantified in a cohort of 162 early treatment naïve NSCLC patients using multiplex-immunofluorescence and related to patient outcome. Expression among different cell-populations was assessed via flow cytometry. Targeted RNA-Seq was performed on CD4 + and CD8 + T cells from digested NSCLC tumor tissue and single-cell RNA-Seq data was analyzed to investigate the functional significance of CD39 + T cell populations. RESULTS: We demonstrate that flow cytometry of early untreated NSCLC patients shows an upregulation of CD39 expression in the tumor tissue among natural killer (NK) cells, fibroblasts and T cells. CD73 expression is mainly found among fibroblasts and Epcam+cells in the tumor tissue. Multiplex Immunofluorescence in a cohort of 162 early untreated NSCLC patients demonstrates that CD39 expression is mainly localized in the tumor stroma while CD73 expression is equally distributed between tumor nest and stroma, and high expression of CD39 and CD73 in the tumor stroma is associated with poor recurrence-free survival (RFS) at 5 years. Additionally, we find that CD8+T cells located in the tumor nest express CD103 and the density of CD39+CD103+CD8+ T cells in the tumor nest predicts improved RFS at 5 years. Targeted RNA-Seq shows that the tumor microenvironment of NSCLC upregulates regulatory pathways in CD4 + T cells and exhaustion in CD8 + T cells, and analysis of a single cell RNA sequencing dataset shows that CD39 + CD4 + cells are enriched in Treg signature gene-sets, and CD39 + CD103 + cytotoxic T lymphocyte show gene signatures indicative of an exhausted cytotoxic phenotype with upregulated expression of CXCL13. CONCLUSIONS: Knowledge of patterns of distribution and location are required to understand the prognostic impact of CD39 + T cell populations in NSCLC. This study provides an improved understanding of spatial and functional characteristics of CD39 + T cells and their significance to patient outcome.

论文信息

作者
Koppensteiner L、Mathieson L、Pattle S、Dorward DA、O'Connor R、Akram AR
单位
Centre for Inflammation Research, The University of Edinburgh, Edinburgh, UK l.koppensteiner@sms.ed.ac.uk.United Kingdom
文献类型
非美国政府资助研究
期刊
Journal for immunotherapy of cancer2023 Aug
原文标识
PubMed 37648263 · DOI 10.1136/jitc-2023-006770